Focus on the Schering-Plough Corporation Company Profile

LYON, France--(Business Wire)--Reportlinker.com announces that a new market research reportrelated to the Pharmaceutical industry is available in its catalogue. Schering-Plough Corporation company profile To order that report: www.reportlinker.com/p064470/Schering-Plough-Corporation-PharmaVitae-Profile.html

(Due to its length, this URL may need to be copied/pasted intoyour Internet browser's address field. Remove the extra space if oneexists.) For more information, contact Nicolas by emailnbo@reportlinker.com , or by phone +33 4 37 65 17 03. This analysis examines the historical and forecast performance forSchering-Plough in the ethical pharmaceutical sector. It encompassesglobal company strategy, portfolio and pipeline analysis andassessment of financial performance, with 1-6 year sales forecasts forkey drugs. An interactive forecasting and analysis tool providescontinually updated quantitative and qualitative information. Scope Benchmark Schering-Plough's performance against key rivals in theethical pharmaceutical sectorAnalyze how Schering-Plough's acquisitionof Organon Biosciences will drive notable therapeutic diversificationfor the companyAssess Schering-Plough's continued forecast recovery

(CAGR of 7.9% out to 2012) following patent expiry for Claritin in2001 CHAPTER 1 EXECUTIVE SUMMARY 2 Key findings 2 Historical and forecast ethical sales performance 4 Therapeutic strategy 7 Launch and expiry outlook 11 Externalization, geographic and molecule type strategies 14 Externalization strategy 15 Geographic strategy 16 Molecule type strategy 17 SWOT analysis 20 Strengths 20 Weaknesses 23 Opportunities 24 Threats 28 CHAPTER 2 CORPORATE HISTORY 34 Key findings 34 Background 35 Key corporate developments 35 M&A history 36 Schering Corp merger with Plough Corp 36 Neogenesis 36 Organon Biosciences 37 M&A strategy 37 Current corporate structure 39 Ethical pharmaceuticals 40 Consumer health 40 Animal health 40 Current management team 41 CHAPTER 3 HISTORICAL PERFORMANCE 42 Key findings 42 Introduction 43 Revenue and growth rate analysis, 2001-06 43 Revenue and growth rate vs. peer set 45 Product analysis, 2001-06 47 Growth drivers 47 Organon M&A 47 Zetia/Vytorin 48 Remicade 48 Growth resistors 48 Claritin 48 Operating revenue and cost analysis, 2001-06 49 Operating revenue/cost analysis 51 CHAPTER 4 FORECAST PERFORMANCE 53 Key findings 53 Introduction 55 Revenue and growth rate, 2006-12 55 Product analysis, 2006-12 57 Growth drivers 61 Zetia/Vytorin 61 MFF258 62 Asenapine 62 Nasonex 62 Remicade 62 Sugammadex 63 Growth resistors 63 Clarinex 63 Rebetol 64 Therapy area analysis, 2006-12 66 CV & hematology 68 CNS 69 Respiratory 70 Immunology & inflammation 71 Urology & sexual health 72 Therapy area focus 73 Launches and expiries analysis, 2006-12 76 Launch portfolio 77 Core portfolio 80 Expiry portfolio 82 Launch/core/expiry configuration 84 Externalization analysis, 2006-12 88 Geographic analysis, 2006-12 94 Molecule type analysis, 2006-12 98 CHAPTER 5 KEY PRODUCTS AND COMPETITORS 104 Key findings 104 Overview 105 Cardiovascular 106 Zetia/Vytorin 106 Overview 106 Sales forecast 107 News flow 108 Competitive landscape 109 Current market assessment 109 Antidyslipidemic market overview 110 Future market assessment 111 Respiratory 113 Nasonex/Asmanex (mometasone franchise) 113 Overview 113 Sales forecast 115 News flow 116 Current market assessment 117 Infectious disease 120 Intron franchise 120 Overview 120 Sales forecast 122 News flow 123 Noxafil 126 Overview 126 Sales forecast 127 News flow 128 Urology & sexual health 131 NuvaRing 131 Overview 131 Sales forecast 132 News flow 133 Competitive landscape 134 Another strong year for Organon's number one growth driver 134 Promotional drive remains key factor in NuvaRing's uptake 134 Contraceptive market overview 135 Future market assessment 139 Puregon 140 Overview 140 Sales forecast 141 News flow 141 Competitive landscape 142 Current market assessment 142 Future market assessment 144 CNS 146 Asenapine 146 Overview 146 Sales forecast 147 News flow 147 Competitive landscape 148 Future market assessment 150 Sugammadex 151 Overview 151 Sales forecast 152 News flow 153 Competitive landscape 153 Clinical trial progression 154 Future market assessment 155 Oncology 157 Temodar 157 Overview 157 Sales forecast 158 News flow 158 Immunology & inflammation 161 Remicade 161 Overview 161 Sales forecast 162 News flow 163 Golimumab 166 Overview 166 Sales forecast 167 R&D pipeline 169 CHAPTER 6 APPENDIX 173 IMS vs. company-reported data reconciliation 173 References 175 List of Tables Table 1: Schering-Plough Corporate Executive Committee 41 Table 2: Peer set overview 45 Table 3: Operating revenue/cost analysis ($m), 2001-06 49 Table 4: Operating cost ratio analysis (% of total revenues),2001-06 51 Table 5: Product portfolio overview, sales ($m), 2006-12 57 Table 6: Therapy area overview, sales ($m), 2006-12 66 Table 7: Launch portfolio overview, sales ($m), 2006-12 77 Table 8: Core portfolio overview, sales ($m), 2006-12 80 Table 9: Expiry portfolio overview, sales ($m), 2006-12 82 Table 10: Externally developed portfolio ($m), 2006-12 88 Table 11: Molecule type overview, sales ($m), 2006-12 98 Table 12: Key products overview 105 Table 13: Zetia/Vytorin: overview 106 Table 14: Zetia/Vytorin: sales forecast ($m), 2006-12 107 Table 15: Zetia/Vytorin: news flow 108 Table 16: Antidyslipidemic market overview, 7MM sales ($m), 2006111 Table 17: Nasonex: overview 113 Table 18: Asmanex: overview 114 Table 19: Nasonex: sales forecast ($m), 2006-12 115 Table 20: Asmanex: sales forecast ($m), 2006-12 115 Table 21: Nasonex/Asmanex: news flow 116 Table 22: Intron franchise: overview 120 Table 23: Rebetol: overview 121 Table 24: Intron A/Peg-Intron: sales forecast ($m), 2006-12 122 Table 25: Rebetol: sales forecast ($m), 2006-12 122 Table 26: Intron franchise: news flow 123 Table 27: Noxafil: overview 126 Table 28: Noxafil sales forecast ($m), 2006-12 127 Table 29: Noxafil: news flow 128 Table 30: NuvaRing: overview 131 Table 31: NuvaRing: sales forecast ($m), 2006-12 132 Table 32: NuvaRing: news flow 133 Table 33: Organon's non-DTC marketing expenditure in 2006 135 Table 34: Top 10 contraceptives in 2006 (7MM) 136 Table 35: Puregon/Follistim: overview 140 Table 36: Puregon/Follistim: sales forecast ($m), 2006-12 141 Table 37: Puregon/Follistim: news flow 141 Table 38: Asenapine: overview 146 Table 39: Asenapine: sales forecast ($m), 2006-12 147 Table 40: Asenapine: news flow 147 Table 41: Sugammadex: overview 151 Table 42: Sugammadex: sales forecast ($m), 2006-12 152 Table 43: Sugammadex: news flow 153 Table 44: Temodar/Temodal: overview 157 Table 45: Temodar: sales forecast ($m), 2005-11 158 Table 46: Temodar: news flow 158 Table 47: Remicade: overview 161 Table 48: Remicade: sales forecast ($m), 2006-12 162 Table 49: Remicade: news flow 163 Table 50: golimumab: overview 166 Table 51: Golimumab: sales forecast ($m), 2006-12 167 Table 52: Schering-Plough's R&D pipeline (Phase I-registration)169 Table 53: Schering-Plough's indication broadening pipeline (PhaseI-registration) 172 Table 54: Exchange rates, 2006 177 List of Figures Figure 1: Historical and forecast ethical sales performance (%CAGR), Schering-Plough and Big Pharma peer set 5 Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006 8 Figure 3: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), Schering-Plough 11 Figure 4: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), Big Pharma 12 Figure 5: Molecule type, externalization and geographic marketdependency (%) vs. peer set, 2006 14 Figure 6: Molecule type, externalization and geographic marketdependency (%) vs. peer set, 2012 15 Figure 7: SWOT analysis of Schering-Plough 20 Figure 8: Therapy area focus, % total sales, 2006 25 Figure 9: Growth driver by company, sales ($m), 2006-12 26 Figure 10: Ethical sales by company, sales ($m), 2006-12 27 Figure 11: Current corporate structure 39 Figure 12: Revenue & growth rate (ethical sales) ($m), 2001-06 43 Figure 13: Ethical revenue ($m) and growth rate (%) vs. peer set,2001-06 46 Figure 14: Growth drivers/resistor products of historical revenueperformance ($m), 2001-06 47 Figure 15: Operating revenue/cost analysis ($m), 2001-06 50 Figure 16: Operating cost ratio analysis (% of total revenues),2001-06 52 Figure 17: Ethical revenue ($m) and growth rate (%), 2006-12 55 Figure 18: Top five products by sales ($m), 2006 59 Figure 19: Top five products by sales ($m), 2012 60 Figure 20: Growth drivers and resistors by product, 2006-12 61 Figure 21: Key strategic products, sales ($m), 2006-12 64 Figure 22: Ethical sales by therapy area ($m), 2006-12 67 Figure 23: Growth drivers and resistors by therapy area (%),2006-12 68 Figure 24: Ethical sales by therapy area ($m), 2006-12 73 Figure 25: Therapy area focus compared with peer set (% totalethical sales), 2006 74 Figure 26: Therapy area focus compared with peer set (% totalethical sales), 2012 75 Figure 27: Launch schedule, sales ($m), 2006-12 79 Figure 28: Core products sales growth ($m), 2006-12 81 Figure 29: Expiry schedule, sales ($m), 2006-12 83 Figure 30: Launch, core and expiry, sales ($m), 2006-12 84 Figure 31: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), Schering-Plough 85 Figure 32: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), peer set 86 Figure 33: Externalization dependency, sales ($m), 2006-12 90 Figure 34: Growth drivers and resistors, externally vs. internallydiscovered products, sales ($m), 2006-12 91 Figure 35: Externalization dependency vs. peer set, % total sales,2006 92 Figure 36: Externalization dependency vs. peer set, % total sales,2012 93 Figure 37: Geographical sales breakdown ($m), 2006-12 94 Figure 38: Growth drivers and resistors by geography, sales ($m),2006-12 95 Figure 39: US dependency vs. peer set, % total sales, 2006 96 Figure 40: US dependency vs. peer set, % total sales, 2012 97 Figure 41: Molecule type sales breakdown ($m), 2006-12 99 Figure 42: Growth drivers and resistors by molecule type, sales

($m), 2006-12 101 Figure 43: Biologics dependency vs. peer set, % total sales, 2006102 Figure 44: Biologics dependency vs. peer set, % total sales, 2012103 Figure 45: Top five antidyslipidemic drug quarterly sales ($m),7MM, 2006 110 Figure 46: Quarterly sales($m) of top five contraceptives, 2006138 Figure 47: Puregon vs. Gonal-F, quarterly sales ($m), 2003-06 143 Figure 48: IMS vs. company-reported ethical sales discrepancy

($m), 2006 174 Figure 49: IMS vs. company-reported ethical sales forecast growthrates (%), 2006-12 175 More market research reports? Go to http://www.reportlinker.comNicolas+33 4 37 65 17 03nbo@reportlinker.comCopyright Business Wire 2007